0
Meta Analysis ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 1 ? Systematic review or meta-analysis. Synthesizes findings across many studies. Strongest evidence. Food & Water Human Health Effects Policy & Risk Sign in to save

Quantifying the collapse of the ventral CA1 excitability margin links emotional memory replay with environmental synchronisation in schizophrenia, depression, and PTSD

2025
Pedro G. P. Rosa

Summary

This paper proposes that when the ventral CA1 excitability buffer narrows below approximately 5 mV due to stress, genetic variants, inflammation, or environmental toxicants including microplastic-derived contaminants, ordinary brain oscillations can trigger involuntary emotional memory replay leading to schizophrenia, depression, or PTSD. The model identifies microplastics as one of several emerging toxicants that may contribute to psychiatric vulnerability.

We introduce the Excitability-Margin Model (EMM), a unifying quantitative framework in which narrowing of the ventral CA1 excitability buffer (ΔVmargin) below ≈ 5 mV allows ordinary hippocampal oscillations (θ, ripple, dendritic plateaus, extracellular K⁺ bursts) to trigger involuntary replay of emotional engrams. A meta-analysis of chronic restraint stress (CRS) recordings reveals four convergent processes — KCC2 down-regulation, NKCC1 up-regulation, loss of GIRK/TASK leak currents, and reduced Na⁺/K⁺-ATPase α1 — that depolarise vCA1 by 11.3 ± 1.5 mV. Additional excitability-narrowing influences include genetic variants (CACNA1C rs1006737 A, SCN2A R1882Q gain-of-function), psychoactive substances (THC, ethanol, nicotine, chronic caffeine), systemic inflammation (viral interleukin-6, cytokine cascades), metabolic shifts (high-sugar diets, insulin resistance), oxidative stress (ROS generation, glutathione depletion), and emerging toxicants such as microplastic-derived contaminants and particulate matter (PM2.5, PM10). Together these risk factors collapse the safety margin to ≤ 5 mV, rendering common network events pathogenic.Once the buffer is breached, the valence of the re-activated engram determines disease trajectory. Fear-biased replays drive dopamine release and sustained cortisol elevation, shifting the glutamate/GABA ratio toward excitation and locking vCA1 into a depolarised state. Repeated activations generate reactive oxygen species, deplete glutathione, and trigger progressive loss of parvalbumin interneurons (PV-INs). The weakening of perisomatic inhibition amplifies excitatory drive, narrows ΔVmargin even further, and permits an expanding range of otherwise benign transients to trigger unwanted engrams — accelerating the shift in excitatory/inhibitory balance and progression toward the schizophrenia phenotype. Sadness-biased loops engage CRF and HPA-axis dysregulation leading to major depressive disorder, while trauma-biased replays recruit noradrenaline bursts evolving toward PTSD. Persistent vCA1 hyperexcitability thus links chronic stress, genetic susceptibility, inflammatory states, metabolic dysfunction, environmental toxicants, and psychoactive exposures into a convergent mechanism of disease.The model also predicts that 7–30 Hz extremely-low-frequency (ELF) magnetic fields, transduced by biogenic magnetite chains, can phase-bias the hippocampal θ-oscillator and increase co-activation probability. Observational studies report associations between geomagnetic storms (Kp ≥ 6) and acute surges in psychiatric hospitalisations, suicide attempts, and cardiovascular events; within EMM, these correlations are interpreted as transient synchronisation and amplification effects in narrow-margin neurons.Long-term remission is expected to require widening ΔVmargin to ≥ 7 mV, with ≈ 9 mV providing robustness against common transients. We outline a Four-Axis Reset (FAR) framework: (i) hyperpolarisation of Vrest, (ii) chloride reset, (iii) PV/KCC2 restoration with ROS reduction, and (iv) narrowing of the γ/θ integration window. Falsifiable, non-invasive operational markers include reduction of on-scalp MEG γ-bursts (≥ 35 %, p < 0.05) and increased heart-rate-variability rMSSD (≥ +5 ms, p < 0.05); exploratory endpoints include ²³Na-MRI (ionic reserve, directional) and PET-KCC2 if tracers become available. Achieving these endpoints in preregistered IRB-approved pilot studies would provide the first in-vivo validation of EMM and authorise progression to RCT II.

Share this paper